ADCT trade ideas
trading it to $30With an ADC platform validated by the FDA approval of ZYNLONTA® and a deep understanding of the oncology treatment landscape, ADCT is working to address significant unmet medical needs and improve outcomes for those with difficult-to-treat hematological cancers and solid tumors.
ADCT: Inverse Head and Shoulders. ADCT broke inverse H&S in NOV. 20. At this moment should be only testing resistance. Stop loss at $32.50 and target is $42.00
